US OptionsDetailed Quotes
XAIR241220C2500
- 0.05
- 0.000.00%
15min DelayClose Dec 3 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume159 Open Interest2.50Strike Price0.00Turnover527.21%IV366.18%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2212Delta0.4780Gamma10.94Leverage Ratio-0.0054Theta0.0000Rho2.42Eff Leverage0.0004Vega
Beyond Air Stock Discussion
Advisory- Alert on Beyond Cancer's Clinical Trial Approval Was Incorrectly Tagged to Beyond Air and Is Being Withdrawn
👀
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
Tuesday, 3rd December at 4:05 pm
• The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent P...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
Monday, 2nd December at 7:30 am
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery
A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare
Strengthened balance sheet is expected to provide sufficient cash runway through June 2026
Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders
Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group
Conference call scheduled for 4:30 p.m. ET today...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Beyond Cancer presented promising preclinical data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy at SITC 2024. The study showed that LV UNO combined with anti-rPD-L1 doubled tumor growth inhibition and improved survival in MAT B III tumor-bearing rats compared t...
No comment yet